Flecainid SAN (flecainide acetate) tablets 50 mg. №30


Manufacturer: Germany

AB AV-nodular persistent tachycardia; arrhythmias associated with wolf-Parkinson-white syndrome and similar disorders caused by the presence of additional pathways ‒ in case of inefficiency of other types of treatment. symptomatic paroxysmal ventricular arrhythmia of a severe degree that threatens the patient’s life, in the absence of a response to other types of therapy. It is also used for intolerance or inability to perform other forms of therapy. џ Paroxysmal atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) in patients with adverse symptoms after conversion, provided there is a clear need for therapy, which is confirmed by the severity of clinical symptoms, if other treatments are ineffective. Before starting use, you should exclude the presence of heart diseases of organic origin and / or violations of the left ventricular ejection fraction, since in this case, the risk of unwanted arrhythmia increases.



Flecainid SAN Storage
active substance: flecainide acetate;

1 tablet contains flecainide acetate 50 mg or 100 mg;

excipients: pregelatinized corn starch, microcrystalline cellulose, corn starch, croscarmellose sodium, magnesium stearate.

Flecainid SAN Dosage form

Flecainid SAN Basic physical and chemical properties:

50 mg tablets: white round, biconvex, uncoated tablets, debossed with “C” on one side and the identifying letters “FI” on the other side;

100 mg tablets: White round, biconvex, uncoated tablets, scored and embossed with the identifying letters “C” above the line and “FJ” below the line, on the other side, the dividing line.

Pharmacotherapeutic group
Antiarrhythmic drugs of class IP. Flecainide. ATX code C01B C04.

Pharmacological properties


Flecainide acetate is a class I antiarrhythmic agent for the treatment of life-threatening symptomatic ventricular arrhythmia and supraventricular arrhythmia of severe severity.

According to its electrophysiological properties, flecainide is a local anesthetic (class IP) with antiarrhythmic action. It is a local amide-type anesthetic, structurally similar to procainamide and encainide, as these substances are also derivatives of benzamide.

Flecainide as a compound of class IP has three main properties: pronounced inhibition of fast sodium channels of the heart; slow onset and shifted kinetic characteristics of sodium channel inhibition (resulting from slow binding and separation from sodium channels); differentiated effect of the drug on the duration of the change in the bioelectric potential of the muscles of the ventricles and Purkinje fibers, namely: no effect on the former and a significant reduction in the duration of the change for the latter. This combination of properties provides a significant reduction in the conductivity of fibers, the depolarization of which depends on fast sodium channels, with a moderate increase in the effective refractory period, as evidenced by the results of studies using isolated cardiac tissues. These electrophysiological properties of flecainide acetate determine the possibility of prolonging the PR interval and the QRS complex on the ECG. At very high concentrations, flecainide causes mild suppression of slow myocardial ducts. This effect is associated with a negative inotropic effect.

Hypersensitivity reaction to flecainide or to any of the excipients.
Heart failure, myocardial infarction in the anamnesis with asymptomatic ventricular ectopia or asymptomatic unstable ventricular tachycardia.
Cardiogenic shock.
Long-term atrial fibrillation, in the treatment of which no attempt was made to convert sinus rhythm, as well as valvular heart disease with significant violations of hemodynamic parameters.
Decreased or impaired ventricular function in the presence of cardiogenic shock, bradycardia of high severity (less than 50 beats per minute), hypotension of high severity.
Use in combination with class I antiarrhythmics (sodium channel blockers).
Brugada syndrome.
In the absence of the possibility of pacing, flecainide should not be used in patients with sinus dysfunction, atrial conduction disorders, atrioventricular block of the second or higher degree, blockade of the leg of the His bundle or blockade of the distal parts.
Asymptomatic ventricular arrhythmia or mild symptoms of ventricular arrhythmia.